Merck's KEYTRUDA Trial Shows Survival Gain in Ovarian Cancer

KEYNOTE-B96 Trial Shows Key Survival Gains

On February 27, 2026, Merck announced that its pivotal Phase 3 KEYNOTE-B96 trial delivered positive results, significantly boosting the outlook for its flagship cancer therapy. The final analysis showed that KEYTRUDA (pembrolizumab), when added to chemotherapy, significantly improved overall survival for patients with platinum-resistant recurrent ovarian cancer. This patient group has historically faced a poor prognosis and limited treatment avenues, making the improvement a noteworthy clinical development.

The trial, also known as ENGOT-ov65, evaluated KEYTRUDA in combination with paclitaxel, with or without bevacizumab. The successful outcome on the key secondary endpoint of overall survival marks a critical step toward establishing KEYTRUDA as a potential standard of care in this new indication.

Data Reinforces KEYTRUDA's Franchise Value

The positive trial data is expected to have a direct commercial impact on Merck. KEYTRUDA, an anti-PD-1 therapy, is already a cornerstone of the company's revenue, and expanding its approved uses is central to Merck's growth strategy. Securing an indication in platinum-resistant ovarian cancer would open a new market for the drug and further solidify its position as a leading oncology treatment.

For investors, this result reinforces the strength and productivity of Merck's research and development pipeline. A successful expansion for a key asset like KEYTRUDA de-risks future earnings and is likely to be received as a bullish signal for the company's stock ($MRK), underscoring its ability to convert clinical success into shareholder value.